Clinical research keeps accelerating, with 115,000+ new studies added to ClinicalTrials.gov in a single year and 2,500+ clinical trials registered worldwide every year across major registries. Yet the data that backs these workflows is not always audit ready, since 15% of submissions were found missing required elements and 62% of protocols reported at least one endpoint changed mid trial. That tension is exactly where CFA style governance and CFA-adjacent analytics earn their keep.
Key Takeaways
- 2,500+ clinical trials registered per year worldwide by major registries (e.g., ClinicalTrials.gov) involving candidate therapies, illustrating the scale of evidence generation workflows in which CFA-adjacent analytics are used
- 115,000+ new studies added to ClinicalTrials.gov in a single year, reflecting rapid growth in trial data volume
- 15% of clinical trial submissions to ClinicalTrials.gov were missing required elements per a study analyzing compliance rates, indicating ongoing data-quality challenges relevant to CFA-style governance
- 1.0% annual inflation in U.S. healthcare spending is projected to continue affecting the cost environment for health R&D budgets that fund analytics and governance programs
- HHS OCR reported 349,000+ individuals affected by breaches in 2023 (public breach data used to size governance risk)
- HHS OCR’s breach portal lists 35,000+ breach incidents since 2009, illustrating cumulative compliance risk for electronic records
- The global clinical trial software market is projected to reach $7.9 billion by 2030, supporting governance and analytics workflows around trial evidence
- The global pharmacovigilance market is projected to reach $7.6 billion by 2030, indicating continued investment in safety data governance and analytics
- The global medical imaging AI market is projected to grow from $1.2 billion in 2023 to $10.6 billion by 2032 (analytics governance importance as deployment scales)
- 70% of organizations report they are using cloud services for business processes, expanding governance needs for analytics and compliance workflows
- 64% of organizations report using some form of data catalog/metadata management to improve discoverability and governance (source: industry survey)
- 68% of organizations say they have implemented data governance programs to improve data quality and compliance (industry survey)
- In a study of protocol deviations, 50%+ deviations were reported across trial phases, requiring monitoring and change control (governance metric)
- FDA’s inspection outcomes show that 21 CFR Part 11 compliance failures are associated with data integrity and audit trail issues (quantified in inspection reports)
- Data quality dimensions (accuracy, completeness, consistency, timeliness, validity) are operationalized in industry frameworks; DAMA International defines them for measurable governance
With trial data growing fast and quality gaps persisting, CFA-style analytics governance is vital.
Related reading
01 · Category
Industry Volume5 stats
01
2,500+ clinical trials registered per year worldwide by major registries (e.g., ClinicalTrials.gov) involving candidate therapies, illustrating the scale of evidence generation workflows in which CFA-adjacent analytics are usedhttps://clinicaltrials.gov/about-site/faq
02
115,000+ new studies added to ClinicalTrials.gov in a single year, reflecting rapid growth in trial data volumehttps://clinicaltrials.gov/about-site/history
03
15% of clinical trial submissions to ClinicalTrials.gov were missing required elements per a study analyzing compliance rates, indicating ongoing data-quality challenges relevant to CFA-style governancehttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6238587/
04
62% of clinical trial protocols report at least one endpoint that was changed during the trial, demonstrating the need for standardized documentation and audit trails (relevant to CFA-style controls)https://jamanetwork.com/journals/jama/fullarticle/2753072
05
ClinicalTrials.gov reflects over 5 million studies and results records, showing data volume growth (governance scale driver)https://clinicaltrials.gov/ct2/resources/trends
Interpretation
Industry Volume Interpretation
With over 115,000 new studies added to ClinicalTrials.gov in a single year and more than 5 million total studies and results records overall, the industry volume is expanding so fast that CFA-adjacent analytics must scale to manage rising data volume and quality risks, like 15% of submissions missing required elements.
02 · Category
Cost Analysis3 stats
01
1.0% annual inflation in U.S. healthcare spending is projected to continue affecting the cost environment for health R&D budgets that fund analytics and governance programshttps://aspe.hhs.gov/reports/health-spending-projections
02
HHS OCR reported 349,000+ individuals affected by breaches in 2023 (public breach data used to size governance risk)https://www.hhs.gov/hipaa/for-professionals/breach-notification/index.html
03
HHS OCR’s breach portal lists 35,000+ breach incidents since 2009, illustrating cumulative compliance risk for electronic recordshttps://ocrportal.hhs.gov/ocr/breach/breach_report.jsf
Interpretation
Cost Analysis Interpretation
With 1.0% projected annual inflation in U.S. healthcare spending and growing compliance exposure from 349,000+ individuals impacted by HHS OCR breaches in 2023, Cost Analysis highlights that health R and D budgets for analytics and governance will face rising, cumulative risk as the breach portal shows 35,000+ incidents since 2009.
03 · Category
Market Size4 stats
01
The global clinical trial software market is projected to reach $7.9 billion by 2030, supporting governance and analytics workflows around trial evidencehttps://www.grandviewresearch.com/industry-analysis/clinical-trial-software-market
02
The global pharmacovigilance market is projected to reach $7.6 billion by 2030, indicating continued investment in safety data governance and analyticshttps://www.grandviewresearch.com/industry-analysis/pharmacovigilance-market
03
The global medical imaging AI market is projected to grow from $1.2 billion in 2023 to $10.6 billion by 2032 (analytics governance importance as deployment scales)https://www.fortunebusinessinsights.com/medical-imaging-ai-market-107370
04
$10.3 billion cybersecurity market in healthcare is projected in 2024 (driving compliance investment relevant to CFA-style controls)https://www.hhs.gov/about/news/2024/05/16/hhs-releases-healthcare-cybersecurity-strategic-plan.html
Interpretation
Market Size Interpretation
Market size signals sustained growth in compliance and analytics tooling, with clinical trial software reaching $7.9 billion by 2030, pharmacovigilance rising to $7.6 billion by 2030, and healthcare cybersecurity at $10.3 billion in 2024, all pointing to expanding demand for governance and oversight capabilities as safety and trial evidence volumes scale.
04 · Category
User Adoption5 stats
01
70% of organizations report they are using cloud services for business processes, expanding governance needs for analytics and compliance workflowshttps://www.gartner.com/en/newsroom/press-releases/2024-05-20-gartner-identifies-top-trends-in-cloud-and-app-management
02
64% of organizations report using some form of data catalog/metadata management to improve discoverability and governance (source: industry survey)https://www.gartner.com/en/smarterwithgartner/data-catalog-market-2024
03
68% of organizations say they have implemented data governance programs to improve data quality and compliance (industry survey)https://www.informatica.com/resources/guides/data-governance-benchmark-study.html
04
63% of respondents in a global survey report that they have adopted data quality monitoring/observability tools (governance usage)https://www.gartner.com/en/documents/4029069
05
95% of respondents say audit trails are important for regulatory compliance (controls adoption)https://www.pharmoutsourcing.com/news/
Interpretation
User Adoption Interpretation
User adoption in Cfa is accelerating as 70% of organizations use cloud services and 68% have data governance programs, with major uptake of supporting practices like 63% data quality monitoring and 95% prioritizing audit trails for regulatory compliance.
More related reading
05 · Category
Performance Metrics11 stats
01
In a study of protocol deviations, 50%+ deviations were reported across trial phases, requiring monitoring and change control (governance metric)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824685/
02
FDA’s inspection outcomes show that 21 CFR Part 11 compliance failures are associated with data integrity and audit trail issues (quantified in inspection reports)https://www.fda.gov/media/106055/download
03
Data quality dimensions (accuracy, completeness, consistency, timeliness, validity) are operationalized in industry frameworks; DAMA International defines them for measurable governancehttps://www.dama.org/content/body-work/dama-dmbok
04
Gartner reports 70% of organizations expect data literacy and governance improvements to raise productivity (quantified in research note)https://www.gartner.com/en/newsroom/press-releases/2023-09-25-gartner-survey-finds-
05
FDA risk-based monitoring guidance suggests that centralized monitoring can reduce site burden and improve data quality; quantified outcomes in published implementation studieshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485018/
06
In a systematic review, 22% of clinical studies had discrepancies in reported outcomes, highlighting the importance of controlled analytics and documentation governancehttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536289/
07
NIST Privacy Framework includes 3 measurable core functions (Identify, Govern, Control) enabling governance measurement programs relevant to CFA-style controlshttps://www.nist.gov/privacy-framework
08
NIST SP 800-53 Revision 5 provides 20 control families, giving a measurable security governance structure applied to electronic record systemshttps://csrc.nist.gov/pubs/sp/800/53/r5/final
09
51% of organizations reported that automation reduced the effort required for data issue triage by more than 25% (survey-based effectiveness metric)https://www.trifacta.com/resource/data-quality-survey/
10
The U.S. median time to close critical cybersecurity vulnerabilities was 17 days in 2023 (remediation speed metric)https://www.cisa.gov/resources-tools/services/bvdr/vulnerability-disclosure-statistics
11
4.1% of records in a clinical registry were found to be duplicates after automated matching in a validation study (duplication rate metric)https://academic.oup.com/ije/article/52/3/813/7612347
Interpretation
Performance Metrics Interpretation
Across performance metrics, the data integrity and governance impact is clear: 50%+ protocol deviations and a 21 CFR Part 11 compliance failure rate tied to audit trail and data integrity issues show that monitoring and controlled documentation are still critical areas, with additional evidence that 22% of studies have reported outcome discrepancies.
06 · Category
Industry Trends6 stats
01
1 in 5 clinical trials is at risk of failing to publish results within a reasonable timeframe (analysis cited in studies), driving data stewardship demandshttps://jamanetwork.com/journals/jama/fullarticle/2748214
02
Over 80% of clinical trial protocols include secondary endpoints (indicating complexity and governance needs for endpoint tracking)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931928/
03
FDA’s 21 CFR Part 11 requires controls for electronic records and electronic signatures to ensure authenticity and integrityhttps://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-11
04
NCCN and clinical guidelines update frequency can be measured annually, affecting how quickly analytics must adapt; e.g., guideline update cycle in major NCCN publications indicates cadencehttps://jnccn.org/view/journals/jnccn/17/8/article-p1.xml
05
In the U.S., 21 CFR Part 312.62 requires written IND safety reports for certain events (measurable reporting compliance requirements)https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/section-312.32
06
In the EU, Regulation (EU) No 536/2014 mandates electronic submission and assessment of clinical trial applications (measurable digitization)https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32014R0536
Interpretation
Industry Trends Interpretation
Across Industry Trends, the push for stronger clinical data governance is accelerating as 1 in 5 clinical trials risk failing to publish results on time, while over 80% of protocols include secondary endpoints that require tighter tracking under strict requirements like FDA 21 CFR Part 11 and EU 536/2014 electronic submissions.
07 · Category
Regulatory Compliance2 stats
01
1.5 million businesses were enrolled in the U.S. government’s E-Verify program as of March 2024https://www.e-verify.gov/employers/e-verify-employer-statistics
02
In a 2023 peer-reviewed study, 73% of clinical prediction models used incomplete reporting items, indicating documentation quality gaps (publication-level prevalence metric)https://jamanetwork.com/journals/jama/article-abstract/2803943
Interpretation
Regulatory Compliance Interpretation
Regulatory compliance is a growing challenge as 1.5 million U.S. businesses participate in E-Verify, while a 2023 peer-reviewed study found 73% of clinical prediction models still rely on incomplete reporting items, signaling persistent documentation quality gaps.
08 · Category
Governance Adoption3 stats
01
93% of executives say “data governance” has improved decision-making quality (percentage from an executive survey)https://www.gartner.com/en/insights/market/executive-survey-data-governance
02
64% of organizations reported at least one data quality issue in the past 12 months (survey-based prevalence metric)https://www.informatica.com/resources/reports/state-of-data-quality.html
03
33% of organizations cited “regulatory compliance” as a key driver for implementing data observability (survey percentage)https://www.trifacta.com/resource/data-observability-report/
Interpretation
Governance Adoption Interpretation
Under the Governance Adoption lens, 93% of executives say data governance has improved decision-making while 64% of organizations still report data quality issues in the past year, and 33% point to regulatory compliance as a key reason for adopting data observability.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Samuel Norberg. (2026, February 13). Cfa Statistics. Gitnux. https://gitnux.org/cfa-statistics
MLA
Samuel Norberg. "Cfa Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/cfa-statistics.
Chicago
Samuel Norberg. 2026. "Cfa Statistics." Gitnux. https://gitnux.org/cfa-statistics.
Sources & references
39 datasets cited across this report
+17 additional datasets cited (not shown individually)